{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:50:17Z","timestamp":1782514217356,"version":"3.54.5"},"reference-count":76,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jval.2026.02.018","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:44:31Z","timestamp":1773852271000},"page":"921-931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Designing and Implementing Real-World Patient-Reported Outcomes\u2014Emerging Recommendations: A Good Practices Report of an ISPOR Task Force"],"prefix":"10.1016","volume":"29","author":[{"given":"Angela J.","family":"Rylands","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konrad","family":"Maruszczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olalekan Lee","family":"Aiyegbusi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meriem","family":"Bouslouk-Marx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Collis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyeka","family":"Illoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Keeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bellinda L.","family":"King-Kallimanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antony","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina L.","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"McMullan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Molsen-David","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Roydhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Yelland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J.","family":"Calvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jval.2026.02.018_bib1","series-title":"Clinical outcome assessment (COA): frequently asked questions","year":"2020"},{"issue":"7","key":"10.1016\/j.jval.2026.02.018_bib6","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jclinepi.2010.02.006","article-title":"The COSMIN study reached international consensus on taxonomy, terminology, and definitions of measurement properties for health-related patient-reported outcomes","volume":"63","author":"Mokkink","year":"2010","journal-title":"J Clin Epidemiol"},{"issue":"16_suppl","key":"10.1016\/j.jval.2026.02.018_bib7","doi-asserted-by":"crossref","first-page":"6611","DOI":"10.1200\/JCO.2023.41.16_suppl.6611","article-title":"Using real-world evidence (RWE) in regulatory decision making: a study of 6 oncology approvals with RWE included in the product label","volume":"41","author":"Zong","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jval.2026.02.018_bib8","doi-asserted-by":"crossref","DOI":"10.1111\/cts.13903","article-title":"Real-world evidence to support regulatory submissions: a landscape review and assessment of use cases","volume":"17","author":"Alipour-Haris","year":"2024","journal-title":"Clin Transl Sci"},{"issue":"14","key":"10.1016\/j.jval.2026.02.018_bib9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1001\/jama.2019.4064","article-title":"The evolving uses of \u201creal-world\u201d data","volume":"321","author":"Basch","year":"2019","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/pds.4975","article-title":"Real-world evidence to support regulatory decision-making for medicines: considerations for external control arms","volume":"29","author":"Burcu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s43441-019-00034-0","article-title":"Measuring the impact of PatientEngagement and patient centricity in clinical Research and Development","volume":"54","author":"Stergiopoulos","year":"2020","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"Liu","year":"2022","journal-title":"BMC Med Res Methodol"},{"issue":"5 Pt 2","key":"10.1016\/j.jval.2026.02.018_bib14","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1475-6773.2010.01142.x","article-title":"Health services research and data linkages: issues, methods, and directions for the future","volume":"45","author":"Bradley","year":"2010","journal-title":"Health Serv Res"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/14737167.2024.2322664","article-title":"Using natural language processing to analyze unstructured patient-reported outcomes data derived from electronic health records for cancer populations: a systematic review","volume":"24","author":"Sim","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib16","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1111\/bcp.13165","article-title":"Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight","volume":"83","author":"Engel","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jval.2026.02.018_bib22","article-title":"MHRA Guidance on the Use of Real-World Data in Clinical Studies to Support Regulatory Decisions","year":"2021","journal-title":"London: Medicines & Healthcare Products Regulatory Agency (MHRA)"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib24","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/pds.4932","article-title":"Trial designs using real-world data: the changing landscape of the regulatory approval process","volume":"29","author":"Baumfeld Andre","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2026.02.018_bib28","series-title":"Guidance for Reporting Real-World Evidence","year":"2023"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/pds.5507","article-title":"HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force","volume":"32","author":"Wang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib30","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","article-title":"Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report","volume":"10","author":"Garrison","year":"2007","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.02.018_bib31","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jval.2024.01.019","article-title":"Assessing real-world data from electronic health records for health technology assessment: the SUITABILITY checklist: a good practices report of an ISPOR task force","volume":"27","author":"Fleurence","year":"2024","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib36","first-page":"17","article-title":"Framework to guide the collection and use of patient-reported outcome measures in the learning healthcare system","volume":"5","author":"Franklin","year":"2017","journal-title":"EGEMS (Wash DC)"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2017.21903","article-title":"Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension","volume":"319","author":"Calvert","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jval.2026.02.018_bib38","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2013.879","article-title":"Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension","volume":"309","author":"Calvert","year":"2013","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jval.2026.02.018_bib39","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11136-018-2048-4","article-title":"Implementing patient-reported outcome measures in clinical practice: a companion guide to the ISOQOL user\u2019s guide","volume":"28","author":"Chan","year":"2019","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jval.2026.02.018_bib40","first-page":"1","article-title":"User\u2019s guide to implementing patient-reported outcomes assessment in clinical practice","volume":"2","author":"Aaronson","year":"2015","journal-title":"Int Soc Qual Life Res"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib43","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/d41573-019-00088-7","article-title":"Harnessing the patient voice in real-world evidence: the essential role of patient-reported outcomes","volume":"18","author":"Calvert","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s41687-022-00466-7","article-title":"Systematic review of guidance for the collection and use of patient-reported outcomes in real-world evidence generation to support regulation, reimbursement and health policy","volume":"6","author":"Maruszczyk","year":"2022","journal-title":"J Patient-Rep Outcomes"},{"issue":"12","key":"10.1016\/j.jval.2026.02.018_bib45","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.drudis.2019.06.009","article-title":"Early Access to Medicines Scheme: real-world data collection","volume":"24","author":"Pang","year":"2019","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib46","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12325-019-00920-x","article-title":"The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview","volume":"36","author":"Contesse","year":"2019","journal-title":"Adv Ther"},{"issue":"23","key":"10.1016\/j.jval.2026.02.018_bib47","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib48","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/pds.4962","article-title":"Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions","volume":"29","author":"Wu","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jval.2026.02.018_bib49","article-title":"Advancing rare disease measurement through the Rare Disease Clinical Outcome Assessment Consortium","volume":"5","author":"Knoble","year":"2024","journal-title":"Ther Adv Rare Dis"},{"issue":"9","key":"10.1016\/j.jval.2026.02.018_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e20157","article-title":"Paving the way for patient centricity in real-world evidence (RWE): qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation","volume":"9","author":"Maruszczyk","year":"2023","journal-title":"Heliyon"},{"issue":"3","key":"10.1016\/j.jval.2026.02.018_bib51","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jnci\/djab177","article-title":"Impact of blinding on patient-reported outcome differences between treatment arms in cancer randomized controlled trials","volume":"114","author":"Efficace","year":"2022","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib52","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1001\/jamaoncol.2018.6205","article-title":"Investigating potential bias in patient-reported outcomes in open-label cancer trials","volume":"5","author":"Roydhouse","year":"2019","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.jval.2026.02.018_bib53","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.jval.2020.12.015","article-title":"Does knowledge of treatment assignment affect patient report of symptoms, function, and health status? An evaluation using multiple myeloma trials","volume":"24","author":"Roydhouse","year":"2021","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2026.02.018_bib54","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad002","article-title":"Assessing the impact of open-label designs in patient-reported outcomes: investigation in oncology clinical trials","volume":"7","author":"Lord-Bessen","year":"2023","journal-title":"JNCI Cancer Spectr"},{"key":"10.1016\/j.jval.2026.02.018_bib55","article-title":"Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study","volume":"368","author":"Moustgaard","year":"2020","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib56","article-title":"The impact of blinding on trial results: a systematic review and meta-analysis","volume":"1","author":"Pitre","year":"2023","journal-title":"Cochrane Evid Synth Methods"},{"key":"10.1016\/j.jval.2026.02.018_bib57","author":"Rylands"},{"issue":"2","key":"10.1016\/j.jval.2026.02.018_bib58","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1524-4733.2005.04054.x","article-title":"Principles of Good Practice for the Translation and Cultural Adaptation Process for patient-reported outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation","volume":"8","author":"Wild","year":"2005","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib59","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1524-4733.2008.00471.x","volume":"12","author":"Wild","year":"2009","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib60","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1524-4733.2008.00470.x","article-title":"Recommendations on evidence needed to support measurement equivalence between electronic and paper-based patient-reported outcome (PRO) measures: ISPOR ePRO Good Research Practices Task Force report","volume":"12","author":"Coons","year":"2009","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.02.018_bib61","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/j.1524-4733.2009.00603.x","article-title":"Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report","volume":"12","author":"Rothman","year":"2009","journal-title":"Value Health"},{"issue":"8","key":"10.1016\/j.jval.2026.02.018_bib62","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","article-title":"Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1--eliciting concepts for a new PRO instrument","volume":"14","author":"Patrick","year":"2011","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib63","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jval.2013.04.002","article-title":"Validation of electronic systems to collect patient-reported outcome (PRO) data-recommendations for clinical trial teams: report of the ISPOR ePRO systems validation good research practices task force","volume":"16","author":"Zbrozek","year":"2013","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib64","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jval.2013.04.004","article-title":"Pediatric patient-reported outcome instruments for research to support medical product labeling: report of the ISPOR PRO good research practices for the assessment of children and adolescents task force","volume":"16","author":"Matza","year":"2013","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib65","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.jval.2014.06.005","article-title":"PRO data collection in clinical trials using mixed modes: report of the ISPOR PRO mixed modes good research practices task force","volume":"17","author":"Eremenco","year":"2014","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2026.02.018_bib66","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","article-title":"Clinical outcome assessments: conceptual foundation-report of the ISPOR clinical outcomes assessment - emerging good practices for outcomes research task force","volume":"18","author":"Walton","year":"2015","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.02.018_bib67","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.jval.2017.05.015","article-title":"Patient-reported outcome and observer-reported outcome assessment in rare disease clinical trials: an ISPOR COA emerging good practices task force report","volume":"20","author":"Benjamin","year":"2017","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib68","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","article-title":"Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force","volume":"20","author":"Powers","year":"2017","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib69","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.jval.2023.01.001","article-title":"Updated recommendations on evidence needed to support measurement comparability among modes of data collection for patient-reported outcome measures: a good practices report of an ISPOR task force","volume":"26","author":"O\u2019Donohoe","year":"2023","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2026.02.018_bib70","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jval.2023.05.003","article-title":"Recommendations on the selection, development, and modification of performance outcome assessments: a good practices report of an ISPOR task force","volume":"26","author":"Edgar","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","article-title":"Developing patient-centered real-world evidence: emerging methods recommendations from a consensus process","volume":"26","author":"Oehrlein","year":"2023","journal-title":"Value Health"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib72","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jval.2020.03.001","article-title":"Criteria and process for initiating and developing an ISPOR good practices task force report","volume":"23","author":"Malone","year":"2020","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.jval.2026.02.018_bib73","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1016\/S1470-2045(25)00520-0","article-title":"SISAQOL-IMI consensus-based guidelines to design, analyse, interpret, and present patient-reported outcomes in cancer clinical trials","volume":"26","author":"Amdal","year":"2025","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.jval.2026.02.018_bib74","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1001\/jama.2022.6421","article-title":"Ethical considerations for the inclusion of patient-reported outcomes in clinical research: the PRO ethics guidelines","volume":"327","author":"Cruz Rivera","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.jval.2026.02.018_bib75","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/s41591-023-02445-x","article-title":"Considerations for patient and public involvement and engagement in health research","volume":"29","author":"Aiyegbusi","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s40271-019-00356-z","article-title":"Patient-community perspectives on real-world evidence: enhancing engagement, understanding, and trust","volume":"12","author":"Oehrlein","year":"2019","journal-title":"Patient Patient-Centered Outcomes Res"},{"issue":"4","key":"10.1016\/j.jval.2026.02.018_bib77","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11606-017-4269-6","article-title":"Twelve lessons learned for effective research partnerships between patients, caregivers, clinicians, academic researchers, and other stakeholders","volume":"33","author":"Witteman","year":"2018","journal-title":"J Gen Intern Med"},{"issue":"6","key":"10.1016\/j.jval.2026.02.018_bib78","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41591-022-01781-8","article-title":"Patient reported outcome assessment must be inclusive and equitable","volume":"28","author":"Calvert","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jval.2026.02.018_bib80","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/jce.16360","article-title":"Who are we missing? Language exclusivity of patient-reported outcomes in atrial fibrillation clinical trials","volume":"35","author":"Lan","year":"2024","journal-title":"J Cardiovasc Electrophysiol"},{"issue":"12","key":"10.1016\/j.jval.2026.02.018_bib81","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1038\/s41591-023-02665-1","article-title":"A toolkit for capturing a representative and equitable sample in health research","volume":"29","author":"Retzer","year":"2023","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jval.2026.02.018_bib83","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41591-024-02827-9","article-title":"Recommendations to address respondent burden associated with patient-reported outcome assessment","volume":"30","author":"Aiyegbusi","year":"2024","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib84","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/j.jval.2023.06.019","article-title":"Perspectives on patient-reported outcome data after treatment discontinuation in cancer clinical trials","volume":"26","author":"King-Kallimanis","year":"2023","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2026.02.018_bib85","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/jamia\/ocab138","article-title":"Digital disparities: lessons learned from a patient reported outcomes program during the COVID-19 pandemic","volume":"28","author":"Sisodia","year":"2021","journal-title":"J Am Med Inform Assoc"},{"key":"10.1016\/j.jval.2026.02.018_bib86","article-title":"Impact of providing an automated telephone option to report weekly patient-reported outcome measures in the PRO-TECT trial (AFT-39) on disparity gaps in symptom management and outcomes","volume":"9","author":"Stover","year":"2025","journal-title":"JCO Clin Cancer Inform"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib87","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/rheumatology\/keaa202","article-title":"Patient adherence with a smartphone app for patient-reported outcomes in rheumatoid arthritis","volume":"60","author":"Colls","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.jval.2026.02.018_bib89","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S1470-2045(19)30790-9","article-title":"International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium","volume":"21","author":"Coens","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib90","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12874-025-02510-8","article-title":"Handling missing values in patient-reported outcome data in the presence of intercurrent events","volume":"25","author":"Thomassen","year":"2025","journal-title":"BMC Med Res Methodol"},{"issue":"6","key":"10.1016\/j.jval.2026.02.018_bib91","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(23)00157-2","article-title":"Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials-Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures","volume":"24","author":"Pe","year":"2023","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jval.2026.02.018_bib92","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1016\/S1470-2045(23)00110-9","article-title":"Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice","volume":"24","author":"Liu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib93","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12874-024-02408-x","article-title":"The role of the estimand framework in the analysis of patient-reported outcomes in single-arm trials: a case study in oncology","volume":"24","author":"Thomassen","year":"2024","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0295080","article-title":"A patient-centred and multi-stakeholder co-designed observational prospective study protocol: example of the adolescent experience of treatment for X-linked hypophosphataemia (XLH)","volume":"19","author":"Saraff","year":"2024","journal-title":"PLOS One"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib96","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s41687-021-00348-4","article-title":"Correction to: validation of a novel patient reported tool to assess the impact of treatment in erythropoietic protoporphyria: the EPP-QoL","volume":"5","author":"Biolcati","year":"2021","journal-title":"J Patient-Rep Outcomes"},{"issue":"7","key":"10.1016\/j.jval.2026.02.018_bib97","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-058782","article-title":"Acute pain pathways: protocol for a prospective cohort study","volume":"12","author":"Jeffery","year":"2022","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.jval.2026.02.018_bib99","doi-asserted-by":"crossref","DOI":"10.1111\/phpp.13012","article-title":"German cohort observational study to investigate the short- and long-term safety and clinical effectiveness of afamelanotide 16 mg (SCENESSE) in patients with Erythropoietic Protoporphyria (EPP)","volume":"41","author":"Homey","year":"2025","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"10.1016\/j.jval.2026.02.018_bib101","author":"Barman-Aks\u00f6zen"},{"issue":"1","key":"10.1016\/j.jval.2026.02.018_bib102","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11136-020-02625-z","article-title":"International guidance on the selection of patient-reported outcome measures in clinical trials: a review","volume":"30","author":"Crossnohere","year":"2021","journal-title":"Qual Life Res"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301526001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T22:29:49Z","timestamp":1782512989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301526001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1098301526001026"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.018","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Designing and Implementing Real-World Patient-Reported Outcomes\u2014Emerging Recommendations: A Good Practices Report of an ISPOR Task Force","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2026.02.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}